Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
12(44%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
4%
Ph not_applicable
2
7%
Ph phase_4
14
52%
Ph phase_3
8
30%

Phase Distribution

0

Early Stage

1

Mid Stage

22

Late Stage

Phase Distribution25 total trials
Phase 2Efficacy & side effects
1(4.0%)
Phase 3Large-scale testing
8(32.0%)
Phase 4Post-market surveillance
14(56.0%)
N/ANon-phased studies
2(8.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

12

trials recruiting

Total Trials

27

all time

Status Distribution
Active(21)
Completed(5)
Other(1)

Detailed Status

Recruiting10
Not yet recruiting8
Completed5
Active, not recruiting2
Enrolling by invitation1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
12
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (4.0%)
Phase 38 (32.0%)
Phase 414 (56.0%)
N/A2 (8.0%)

Trials by Status

recruiting1037%
completed519%
active_not_recruiting27%
not_yet_recruiting830%
enrolling_by_invitation14%
unknown14%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT06008197Phase 3

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Recruiting
NCT07523867Phase 4

Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study

Not Yet Recruiting
NCT07547878Phase 4

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

Active Not Recruiting
NCT07537088Phase 4

Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

Not Yet Recruiting
NCT06058585Phase 3

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Recruiting
NCT07442448Phase 4

Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure

Enrolling By Invitation
NCT06094920Phase 4

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Completed
NCT07351864Phase 4

Finerenone Plus SGLT2 Inhibitors in Heart Failure

Not Yet Recruiting
NCT07326631Not Applicable

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Not Yet Recruiting
NCT07270367Phase 3

Finerenone and Cardiac Remodeling

Not Yet Recruiting
NCT07239570Phase 4

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

Recruiting
NCT07235891Phase 4

Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease

Not Yet Recruiting
NCT05901831Phase 3

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Completed
NCT06381323Phase 4

The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism

Completed
NCT07056595Not Applicable

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

Recruiting
NCT06838416

Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease

Recruiting
NCT06835322Phase 2

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Recruiting
NCT06024746Phase 3

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

Recruiting
NCT06033950Phase 3

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists

Recruiting
NCT06727409Phase 4

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
27